NEW YORK (GenomeWeb News) – MDxHealth today announced it will be sharing a $1.1 million grant with NovioGendix to develop tumor markers for bladder cancer.
The grant comes from Eurotrans-Bio, a European Commission initiative to foster cross-border R&D between companies and academia in the biotechnology space.
MDxHealth and NovioGendix together will use the funds to discover and validate tumor markers that may be predictive of tumor progression into the muscle in developing invasive-stage bladder cancer. The partners will use DNA methylation technologies, DNA sequencing, and RNA expression profiles on clinical samples collected from bladder cancer patients from the urology department at Radboud University Nijmegen Medical Centre in the Netherlands.
NovioGendix is a molecular diagnostics firm spun out of RUNMC.